Medicare's 2027 Part D Cap Is $2,400. You Need $7,500 of Drugs to Reach It.

$700 is a ceiling, not a bill. A news item syndicated across finance sites on August 28 said Medicare's 2027 drug deductible is $700 and you pay all of it before your plan pays anything. The number is right, the sentence is wrong. And the figure that governs your year is neither $700 nor $2,400. It's $7,500.

Part D pays in three stages, and 2027 sets them here. You pay the full retail price of your prescriptions until your spending reaches your plan deductible, which can be anything from $0 to $700. Above that line you pay 25% of retail. Once your own payments add up to $2,400, covered drugs cost you nothing for the rest of the year.

Reaching that third stage takes $7,500 of retail drug cost, up $945 from 2026. None of the ten pages ranking for the 2027 deductible publishes that number, and it's the one that tells you whether any of this touches you. Every figure below was read from CMS pages on August 31, 2026.

The $85 increase is a change in the maximum, not in your bill

CMS sets the deductible as a ceiling on what a plan may charge, and plans compete underneath it. Some set $0. Some set a middle figure. Some apply the deductible only to higher drug tiers, so a reader whose prescriptions are all generics never touches it. The $85 increase reaches you only if your plan was already charging the maximum and decides to stay there in 2027.

Here is what actually moved between the two years.

The first two rows come from the CMS 2027 Rate Announcement of April 6, 2026. The premium row comes from a separate CMS release on July 28, 2026. That 6.0% isn't what plans decided to charge; it's the most the Inflation Reduction Act lets the base figure rise in a year, and 2027 hit the limit. There's a second reason to watch this row: through 2026, a CMS program paid insurers to hold premiums down, and CMS says it ends after this year. The 6% cap protects only the base figure, not your plan's actual sticker price, so your own premium can move by more. What I can't compute for you yet is that sticker price, because the plan-by-plan landscape publishes in mid-to-late September.

Here's what actually costs you money. The $300 on the cap, if your prescriptions are expensive enough to reach it. The $2.34 a month on the base premium that your plan premium is built from, whatever you take. The $85 on the deductible ceiling, the number that carried the headline, costs most people nothing at all.

$7,500 is where drugs go free, and the formula is one line

So where does $7,500 come from? Two lines of arithmetic, and neither of them needs anything the government has not already published. Your out-of-pocket cost equals the deductible plus 25% of everything above the deductible. Turn that around and the retail spend needed to reach the cap is the deductible plus the remaining cap divided by 0.25.

For 2027: $700 + ($2,400 - $700) / 0.25 = $700 + $6,800 = $7,500.

Run the same line on 2025, where the deductible was $590 and the cap was $2,000, and it returns $6,230, the figure CMS and KFF both published for that year. The formula reproduces a known answer exactly, so the 2027 output is a calculation rather than a guess. On 2026 figures it returns $6,555.

Notice the shape. Your money moves fastest in the first $700 and stops moving after $7,500, which is the opposite of the way the headline reads.

What it does to two prescription bills

Say your prescriptions run $2,800 a year at the pharmacy counter price, which is roughly three brand-name maintenance drugs, and your plan charges the full deductible. You pay the first $700 yourself, then a quarter of the remaining $2,100, which is $525. Your year costs $1,225. Run the same $2,800 through the 2026 rules, with their $615 deductible, and you'd have paid $1,161.25. The redesign costs you $63.75.

That $63.75 is the entire 2027 change for you, and it's 21% of the $300 the cap rose by. The rest of the increase lands on people who reach the cap, so take one of them: a neighbor whose specialty drug carries $7,500 of retail cost. In 2027 she pays $700 plus 25% of $6,800, which is exactly $2,400, so she lands on the cap. Under 2026 rules that same $7,500 would have produced $2,336.25 in cost sharing, above the $2,100 cap, so she paid $2,100. Her increase is the full $300.

Both cases hold retail drug prices constant between the years, which is the only way to separate the benefit design change from the drugs themselves getting cheaper or dearer. Your actual bill moves with both.

A $0-deductible plan is worth $525, and $43.75 a month decides it

The advantage of waiving the deductible is a fixed number, and it's smaller than most shoppers assume.

On the first $700 of retail cost, a standard plan takes 100% from you and a $0-deductible plan takes 25%. The difference is 75 cents on each of those dollars, or $525, and that's the entire advantage. It doesn't grow. A reader with $2,800 of retail cost saves $525, and a reader with $28,000 of retail cost saves the same $525.

Divide $525 by twelve and you get $43.75 a month. That single figure settles the plan comparison the deductible headline is trying to start. If the $0-deductible plan costs $20 a month more, take it. If it costs $60 more, it's the worse deal by about $195 a year.

There's a trade on the other side, and it sounds backwards until you see it: paying less per dollar means it takes longer to reach the cap. On the standard plan your drugs go free once retail cost hits $7,500. Without a deductible that point moves to $9,600, because a quarter of every dollar has to add up to $2,400, and there's no 100% stage piling up your out-of-pocket total early. I lean toward taking the $525 whenever the premium allows it, since most enrollees never approach either point, but anyone on a specialty drug should price both.

GPT knew all three 2027 figures without being told, and that's not the useful part

Your ANOC numbers are the input and a chatbot is a perfectly good calculator for them, which is a recommendation worth testing before making it. So I handed the same problem to GPT with no web access, no files and no answer key, asking first what it remembered and then handing it the rules.

Recall came back correct: $700, $2,400 and $7,500 from memory alone, which is not what happened the last time I tested a model on 2027 figures. On the supplied rules it then matched my arithmetic to the dollar.

Recall isn't verification, so the figures were checked against the CMS fact sheets and not the other way round. The real limit sits somewhere else, and no better model removes it. Every number in that transcript describes the standard benefit, the reference design CMS publishes. Your plan is a variation on it, and the variation is printed in a letter that no model can read.

Three numbers to pull out of the letter arriving by September 30

Your plan has to deliver an Annual Notice of Change, the ANOC, no later than September 30. It states what changes about your coverage on January 1, and it's the only place your own figures live. Four dates decide what you can do about them.

• Mid-to-late September. CMS publishes final 2027 premiums and the plan landscape, which is when plans become comparable.
• By September 30. Your ANOC arrives with your own deductible, premium and drug tiers for 2027.
• October 15 to December 7. Annual Enrollment, the one window where a switch takes effect January 1.
• January 1, 2027. New coverage starts, and negotiated prices on 15 more drugs take effect.

Read the ANOC for three figures and skim the rest. Your 2027 deductible, which is the only version of the $700 that applies to you. Whether that deductible covers every tier or only the higher ones. Your 2027 monthly premium, which is what you compare against $43.75 if a plan without a deductible is on your list.

With those three numbers the arithmetic above becomes yours: multiply the retail price of your prescriptions by twelve, subtract your deductible, take a quarter of the rest, and add the deductible back. Any chatbot will do that correctly once you type your own figures into it, as the run above shows.

One note on that last date. The 15 drugs getting negotiated prices include the semaglutide family sold as Ozempic and Wegovy, and CMS projects about $685 million in out-of-pocket savings for beneficiaries across the group. If one of them is on your list, the retail number you feed into the formula changes on the same day the formula does.

What this arithmetic does not cover

The $2,400 cap is narrower than the phrase out-of-pocket cap suggests, and three kinds of spending sit outside it.

Only covered drugs on your plan formulary count. A drug your plan doesn't cover contributes nothing toward the $2,400 and doesn't stop at it. Premiums sit outside the cap as well, so a full year costs your monthly premium times twelve, plus up to $2,400 in drug cost sharing, plus anything off formulary. Drugs administered in a doctor's office generally fall under Part B rather than Part D, with separate cost sharing that this cap never touches.

The 2027 Part B premium and the IRMAA income brackets aren't published yet. CMS releases them in November, so anyone adding up a total 2027 Medicare cost today is working with half the bill. This article covers drug cost sharing under Part D and nothing else. If you're under 65 and shopping for coverage, the 2027 ACA subsidy cliff is the equivalent arithmetic on the Marketplace side, and if you're working out what your 2027 income looks like in the first place, the Social Security COLA calculation sets the other half of it. And when a charge does arrive that the cap was supposed to stop, checking a medical bill for errors is the step before disputing it.

FAQ

How much do I have to spend on prescriptions before Medicare pays 100% in 2027?

About $7,500 of retail drug cost, if your plan charges the full $700 deductible. The 2027 standard benefit takes 100% of retail from you up to the deductible, 25% after that, and nothing once your own payments reach $2,400. Solving for the retail total gives $700 plus $6,800, so $7,500 in all; the $6,800 is the gap between the cap and the deductible ($2,400 minus $700 is $1,700) divided by 0.25. The same formula on 2026 figures of $615 and $2,100 gives $6,555, and on 2025 figures of $590 and $2,000 it gives $6,230, the number CMS and KFF published for that year. So the spending needed to reach free drugs climbs by $945 while the money leaving your pocket climbs by $300. If your plan waives the deductible, the threshold moves to $9,600, because paying 25% from the first dollar takes longer to accumulate $2,400. Only covered drugs on your plan formulary count toward the cap.

Is the $700 Part D deductible for 2027 mandatory for every plan, or can a plan charge less?

A plan can charge less, and many do. The $700 is the statutory maximum CMS set for 2027, which is the highest deductible a Part D plan is allowed to impose. Plans set anything from $0 up to that ceiling, and some apply the deductible only to higher drug tiers so generics skip it entirely. The figure that governs your year is printed in the Annual Notice of Change your plan must deliver by September 30, 2026. The $85 increase over the 2026 ceiling of $615 reaches you only if your plan sat at the maximum and chooses to stay there. That is why a headline saying you pay $700 before your plan pays anything is describing a legal limit rather than the bill of anyone in particular.

Is a $0-deductible Part D plan worth it in 2027?

It is worth exactly $525 a year in cost sharing, so the premium decides it. Waiving the deductible saves you 75 cents on each of the first $700 of retail cost, because you pay 25% there instead of 100%, and 0.75 times $700 is $525. That advantage is flat for anyone whose retail drug cost passes $700 and it does not grow with spending. Divide by twelve and the break-even premium is $43.75 a month. Pay more than that in extra premium and the $0-deductible plan loses on this comparison. There is a trade on the other side: because your out-of-pocket total climbs at 25 cents on the dollar from the start, the point where drugs go free moves from $7,500 of retail cost to $9,600.

What changes in Medicare Part D between 2026 and 2027?

Four numbers move. The deductible ceiling rises from $615 to $700, the annual out-of-pocket cap from $2,100 to $2,400, the base beneficiary premium from $38.99 to $41.33, and the retail spend needed to reach the cap from $6,555 to $7,500. Coinsurance in the middle phase stays at 25%. The 6.0% rise in the base premium is the maximum the Inflation Reduction Act allows for that figure, and it lands in the first year without the Part D premium stabilization demonstration, which CMS is ending after 2026 to return the program to traditional market conditions. Negotiated prices for 15 more Part D drugs, including the semaglutide family sold as Ozempic and Wegovy, take effect January 1, 2027, with CMS projecting about $685 million in beneficiary savings. Final 2027 premiums and the plan landscape publish in mid-to-late September 2026.

Sources

• Centers for Medicare & Medicaid Services, 2027 Medicare Advantage and Part D Rate Announcement fact sheet, April 6, 2026 (the $700 deductible maximum, the $2,400 annual out-of-pocket threshold, and the 25% coinsurance in the initial coverage phase): https://www.cms.gov/newsroom/fact-sheets/2027-medicare-advantage-part-d-rate-announcement
• Centers for Medicare & Medicaid Services, Medicare Part D 2027 National Average Monthly Bid Amount Information, July 28, 2026 (base beneficiary premium of $41.33 against $38.99 in 2026, the discontinuation of the Part D premium stabilization demonstration at the end of CY 2026, and the mid-to-late September release of final premiums and the plan landscape): https://www.cms.gov/newsroom/fact-sheets/medicare-part-d-2027-national-average-monthly-bid-amount-information
• Centers for Medicare & Medicaid Services, Selected Drugs and Negotiated Prices, Medicare Drug Price Negotiation Program (15 additional Part D drugs with negotiated prices effective January 1, 2027, including the semaglutide products, and projected beneficiary out-of-pocket savings of about $685 million): https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices
• Medicare.gov, plan notices and enrollment periods (the September 30 deadline for plans to deliver the Annual Notice of Change, and Annual Enrollment running October 15 to December 7 for coverage effective January 1): https://www.medicare.gov
• CMS and KFF published figures for the 2025 standard benefit, a $590 deductible and a $2,000 out-of-pocket cap reached at about $6,230 of total drug costs. Used here only to check that the formula reproduces a published threshold.
• Cold run transcript, GPT (gpt-5.6-sol) through the Codex CLI, August 31, 2026, single turn, no web access and no files, with the memory question asked before any rules were supplied.

Disclaimer

This is an educational explainer about published federal rules, not medical, insurance or financial advice, and none of it is specific to your situation. The deductible ceiling, out-of-pocket cap, coinsurance rate and base beneficiary premium are published CMS figures for 2027, stated as of August 31, 2026. Every out-of-pocket amount here is computed from the standard benefit design, and your plan may set a lower deductible, a different formulary and different tier rules, all of which change the result. The worked cases hold retail drug prices constant between 2026 and 2027 to isolate the benefit design change, so they are not a forecast of your bill. Final 2027 plan premiums publish in mid-to-late September 2026, and the 2027 Part B premium and IRMAA brackets publish in November 2026. Check your own Annual Notice of Change and the Medicare Plan Finder before making an enrollment decision.